---
title: "Project BioShield funding for Ebola countermeasures"
description: "CBRNe World provides those tasked with defending against CBRN and IED threats with the essential practical, scientific and political information. Access the current and previous issues of the magazine by registering as a member."
url: "https://cbrneworld.com/news/subscribers/project-bioshield-funding-for-ebola-countermeasures"
date: "2026-07-30T21:09:33+00:00"
language: "en-GB"
---

#  Project BioShield funding for Ebola countermeasures

 Written by CBR on 03 October 2017.

Announced on October 2nd, the US Department of Health and Human Services (HHS) has allocated the first funding under Project BioShield for Ebola countermeasures.
This funding will add add two vaccines and two treatments to the Strategic National Stockpile (SNS): a single-dose vaccine licensed by Merck, a prime-boost vaccine regimen from Johnson & Johnson, and monoclonal antibody treatments from Mapp Biopharmaceutical and Regeneron Pharmaceuticals.
The $170.2 million in Project BioShield funds covers late-stage development and buys up to 1.13 million vaccine regimens and an unspecified number of treatment courses of the two drugs.

## Schema

```json
{ "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "News", "item": "https://cbrneworld.com/news" }, { "@type": "ListItem", "position": 2, "name": "Subscribers", "item": "https://cbrneworld.com/news/subscribers" }, { "@type": "ListItem", "position": 3, "name": "Project BioShield funding for Ebola countermeasures", "item": "https://cbrneworld.com/news/subscribers/project-bioshield-funding-for-ebola-countermeasures" } ] }
```

```json
{ "@context": "https://schema.org", "@type": "NewsArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://cbrneworld.com/news/subscribers/project-bioshield-funding-for-ebola-countermeasures" }, "headline": "Project BioShield funding for Ebola countermeasures", "description": "Announced on October 2nd, the US Department of Health and Human Services (HHS) has allocated the first funding under Project BioShield for Ebola countermeasures.This funding will add add two vaccines and two treatments to the Strategic National Stockpile (SNS): a single-dose vaccine licensed by Merck, a prime-boost vaccine regimen from Johnson & Johnson, and monoclonal antibody treatments from Mapp Biopharmaceutical and Regeneron Pharmaceuticals.The $170.2 million in Project BioShield funds covers late-stage development and buys up to 1.13 million vaccine regimens and an unspecified number of treatment courses of the two drugs.", "image": { "@type": "ImageObject", "url": "https://cbrneworld.com/" }, "publisher": { "@type": "Organization", "name": "CBRNe World Magazine", "logo": { "@type": "ImageObject", "url": "https://cbrneworld.com/images/default/Asset%201.png" } }, "author": { "@type": "Person", "name": "Ben Bray", "url": "https://cbrneworld.com/news/subscribers/project-bioshield-funding-for-ebola-countermeasures" }, "datePublished": "2017-10-03T14:19:18+01:00", "dateCreated": "2017-10-03T14:19:18+01:00", "dateModified": "2018-12-14T15:55:28+00:00" }
```